{"ModuleTitle": "Company Description", "CompanyName": "Heat Biologics, Inc.", "Symbol": "HTBX", "Address": "627 DAVIS DRIVE SUITE 400, MORRISVILLE, North Carolina, 27560, United States of America", "Phone": "919-240-7133", "Industry": "Major Pharmaceuticals", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "We are a biopharmaceutical company engaged in the development of\r\nimmunotherapies, vaccines and diagnostics. Our gp96 platform is designed to\r\nactivate the immune system. This platform has broad applications in cancer and\r\ninfectious disease. Our T-cell Activation Platform (TCAP), leverages gp96's role\r\nas a natural molecular warning system to secrete cancer antigens. TCAP includes\r\ntwo variations for intradermal administration, Immune Pan-antigen Cytotoxic\r\nTherapy (ImPACT\u00ae) and Combination Pan-antigen Cytotoxic Therapy (ComPACT(TM)).\r\nHS-110 (viagenpumatucel-L) is our first allogeneic (\"off-the-shelf\") cell line\r\nbiologic product candidate in a series of proprietary ImPACT\u00ae based\r\nimmunotherapies designed to stimulate a patient's own T-cells to destroy cancer.\r\nHS-130 is an allogeneic cell line engineered to express the extracellular domain\r\nof OX40 ligand fusion protein (OX40L-Fc), a key costimulator of T-cells, with\r\nthe potential to augment antigen-specific CD8+ T-cell response.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f03%2f30%2f0001553350-20-000252.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "Jeff A. Wolf", "title": "Chairman, President & Chief Executive Officer"}, {"name": "Jeff T. Hutchins", "title": "Chief Operating & Scientific Officer"}, {"name": "Lori McDermott", "title": "Vice President-Clinical Development"}], "Number_of_employees": ["NO INFO"], "Subsidiaries": ["NO INFO"]}